The CEO's statement highlights the negative impact of the Zantac litigation on GSK's stock. While the confidence expressed may provide some reassurance to investors, the acknowledgment of the issue as an 'overhang' suggests that it is a significant concern that could continue to weigh on the stock price in the short term. The score reflects the potential negative sentiment among investors due to the ongoing legal battles.